Tabitha Rajasaari
Nurse Practitioner · Chattanooga, TNNPI 1467124321
Payments from drug & device makers
Across 183 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$526
- UCB, Inc.$341
- Teva Pharmaceuticals USA, Inc.$303
- Neurocrine Biosciences, Inc.$243
- AstraZeneca$225
- Neurelis, Inc.$196
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,67498%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $526 |
| UCB, Inc. | 14 | $341 |
| Teva Pharmaceuticals USA, Inc. | 17 | $303 |
| Neurocrine Biosciences, Inc. | 16 | $243 |
| AstraZeneca(2 entities) | 8 | $225 |
| Neurelis, Inc. | 6 | $196 |
| Pfizer | 10 | $168 |
| Alnylam Pharmaceuticals Inc. | 7 | $168 |
| Lundbeck LLC | 6 | $148 |
| Tanabe Pharma America, Inc. | 7 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $135 |
| Jazz Pharmaceuticals Inc. | 4 | $103 |
| SK Life Science, Inc. | 4 | $96 |
| TG Therapeutics, Inc. | 3 | $95 |
| Grifols USA, LLC | 3 | $72 |
| Amneal Pharmaceuticals LLC | 3 | $68 |
| Axsome Therapeutics, Inc. | 2 | $66 |
| Ipsen Biopharmaceuticals, Inc | 3 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Biogen | 2 | $55 |
| Kedrion Biopharma, Inc. | 2 | $46 |
| Argenx US, Inc. | 2 | $45 |
| Johnson & Johnson(2 entities) | 2 | $42 |
| Novartis | 2 | $42 |
| EMD Serono, Inc. | 2 | $42 |
| Acadia Pharmaceuticals Inc | 2 | $40 |
| ITF Therapeutics LLC | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Aucta Pharmaceuticals, Inc. | 1 | $26 |
| Merz Pharmaceuticals, LLC | 1 | $26 |
| Catalyst Pharmaceuticals, Inc. | 1 | $26 |
| CSL Behring | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Insightec,inc | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$3,749 in reported general payments places this provider in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 14 | $10,946 |
| Levetiracetam | 18 | $518 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Chattanooga
- Cynthia WilsonChattanooga$62K
- Honor HightshueChattanooga$45K
- Amy OttmanChattanooga$32K
- Philip AndrewsChattanooga$18K
- Amberly EllisChattanooga$17K
- Erin StockwellChattanooga$15K
- Teresa DeeseChattanooga$13K
- Jay PassmoreChattanooga$13K
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.